Lawyer profile for Greater China Region 2022
Chambers Research is conducted by 200 Research Analysts, across 200 jurisdictions and provides nearly 6,000 rankings tables. Annually we collect hundreds of thousands of responses from clients, the majority via in-depth interview. Learn more about our methodology.
Greater China Region
Healthcare (PRC Firms) - China
Corporate Investigations/Anti-Corruption (PRC Firms) - China
This content is provided by Alan Zhou
Alan Zhou's practice is focused in the areas of mergers & acquisitions, private equity/venture capital, regulatory compliance, and general corporate. Mr. Zhou has a particularly strong background in pharmaceutical and healthcare industrial sectors.
Mr. Zhou has been seconded as general counsel for China operations of Boehringer Ingelheim, a leading multinational pharmaceutical company, for more than nine years, and is responsible for various legal matters including general corporate, acquisitions and joint venture formation, compliance and regulatory, intellectual property and corporate restructuring.
Mr. Zhou is the standing director of CEIBS Alumni Healthcare Association and is also an investment partner of HGI FINAVES China Fund.
Mr. Zhou has represented many multinational corporations, reputable Chinese state owned and private corporations, and private equity/venture capital funds. Mr. Zhou has not only worked for reputable Chinese private companies such as Focus Media, VIPShop, Acorn International, Hisoar Pharmaceutical, Tianyuan Biopharm, and GeneScience Pharma, he has also advised PRC state owned companies such as Shanghai Dasheng, Shanghai Industrial and Shanghai Airport Authority. In the area of PE/VC, Mr. Zhou has acted for CBRE Investors, Colony Capital, Navis Capital, Lightspeed Ventures, Qiming Ventures, DT Capital, NEA, New Alliance Capital, Warden International, WINS and other international and local PE/VC funds.
Global Law Office